Effects of collagen peptide supplementation on cardiovascular markers: a systematic review and meta-analysis of randomised, placebo-controlled trials
Zahra Jalili, Faramarz Jalili, Sajjad Moradi, Reza Bagheri, Seyedeh Parisa Moosavian, Fatemeh Naeini, Hamed Mohammadi, Seyed Mojtaba Ghoreishy, Alexei Wong, Nikolaj Travica, Mohammad Ali Hojjati Kermani, Cyrus Jalili
Abstract
Abstract Previous studies have advocated that collagen peptide supplementation (CPS) can positively affect cardiovascular health. However, the widespread impact of CPS on CVD-related markers is not fully resolved. Consequently, the current systematic review and meta-analysis aimed to assess the efficacy of CPS on CVD-related markers. A systematic search in the Scopus, PubMed and ISI Web of Science databases were completed to identify relevant randomised, placebo-controlled trials (RCT) published up to November 2021. Mean Differences were pooled using a random-effects model, while publication bias, sensitivity analyses and heterogeneity were assessed using previously validated methods. Twelve RCT, comprising of a total of eleven measured markers, were selected for the quantitative analysis. Pooled data revealed that CPS significantly decreased fat mass (–1·21 kg; 95 % CI: −2·13, −0·29; I 2 = 0·0 %; P = 0·010) and increased fat-free mass, based on body mass percentage (1·49 %; 95 % CI: 0·57, 2·42; I 2 = 0·0 %; P = 0·002). Moreover, collagen peptide supplementation led to a significant decrease in serum LDL (–4·09 mg/dl; 95 % CI: −8·13, −0·04; I 2 = 93·4 %; P = 0·048) and systolic blood pressure (SBP) (–5·04 mmHg; 95 % CI: −9·22, −0·85; I 2 = 98·9 %; P = 0·018). Our analysis also indicated that CPS did not affect glycemic markers. Our outcomes indicate that CPS reduces fat mass, LDL and SBP while increasing fat-free mass. Future investigations with longer CPS duration are needed to expand on our results.